Research ArticleCancer

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

See allHide authors and affiliations

Science Translational Medicine  07 Aug 2019:
Vol. 11, Issue 504, eaax7392
DOI: 10.1126/scitranslmed.aax7392

Article Information

vol. 11 no. 504

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication September 23, 2018
  • Resubmitted April 17, 2019
  • Accepted for publication July 3, 2019
  • .

Author Information

  1. Bradon R. McDonald1,
  2. Tania Contente-Cuomo1,
  3. Stephen-John Sammut2,
  4. Ahuva Odenheimer-Bergman1,
  5. Brenda Ernst3,
  6. Nieves Perdigones1,
  7. Suet-Feung Chin2,
  8. Maria Farooq1,
  9. Rosa Mejia4,
  10. Patricia A. Cronin3,
  11. Karen S. Anderson3,5,
  12. Heidi E. Kosiorek3,
  13. Donald W. Northfelt3,
  14. Ann E. McCullough3,
  15. Bhavika K. Patel3,
  16. Jeffrey N. Weitzel4,
  17. Thomas P. Slavin4,
  18. Carlos Caldas2,
  19. Barbara A. Pockaj3,* and
  20. Muhammed Murtaza1,3,*
  1. 1Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
  2. 2Department of Oncology and Cancer Research UK Cambridge Institute and Cancer Centre, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
  3. 3Mayo Clinic, Scottsdale, AZ 85259, USA.
  4. 4City of Hope, Duarte, CA 91010, USA.
  5. 5Biodesign Institute, Arizona State University, Tempe, AZ 85281, USA.
  1. *Corresponding author. Email: mmurtaza{at}tgen.org (M.M.); pockaj.barbara{at}mayo.edu (B.A.P.)

Altmetric

Article usage

Article usage: August 2019 to November 2019

AbstractFullPdf
Aug 20191739117553576
Sep 20191268367240
Oct 2019988209188
Nov 20192608276